PCVX Stock Analysis: Buy, Sell, or Hold?
PCVX - Vaxcyte, Inc. Common Stock
$57.03
-1.18 (-2.03%)
▼
5d:
+0.12%
30d:
+25.56%
90d:
-6.32%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 05, 2026
22d
Get Alerted When PCVX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PCVX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: PCVX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PCVX is currently trading at $57.03, which is considered extended relative to its 30-day fair value range of $47.42 to $56.91.
Technical Outlook: Technically, PCVX is in a downtrend. The price is currently testing key support at $55.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PCVX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $109.00 (+87.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PCVX is in a downtrend. The price is currently testing key support at $55.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PCVX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $109.00 (+87.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$47.42 -
$56.91
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 87.3% below Wall St target ($109.00)
Trading Range Analysis
30-Day Trading Range
$47.42 -
$56.91
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$55.38
Resistance Level
$61.77
Current Trend
Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.84
Wall Street Target
$109.00
(+87.3%)
Share & Embed Analysis
Last updated: July 13, 2026 4:20 PM ET
Data refreshes hourly during market hours. Next update: 5:20 PM
Data refreshes hourly during market hours. Next update: 5:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCVX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Elvia Cowan
SELL
3000 shares
2026-04-07
Elvia Cowan
SELL
1892 shares
2026-03-17
Elvia Cowan
SELL
2500 shares
2026-03-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 66 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 64 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 50 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$124 | 61 BUY |
